Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension.

Although inhaled NO (iNO) therapy is often effective in treating infants with persistent pulmonary hypertension of the newborn (PPHN), up to 40% of patients fail to respond, which may be partly due to abnormal expression and function of soluble guanylate cyclase (sGC). To determine whether altered sGC expression or activity due to oxidized sGC contributes to high pulmonary vascular resistance (PVR) and poor NO responsiveness, we studied the effects of cinaciguat (BAY 58-2667), an sGC activator, on pulmonary artery smooth muscle cells (PASMC) from normal fetal sheep and sheep exposed to chronic intrauterine pulmonary hypertension (i.e., PPHN). We found increased sGC α(1)- and β(1)-subunit protein expression but lower basal cGMP levels in PPHN PASMC compared with normal PASMC. To determine the effects of cinaciguat and NO after sGC oxidation in vitro, we measured cGMP production by normal and PPHN PASMC treated with cinaciguat and the NO donor, sodium nitroprusside (SNP), before and after exposure to 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, an sGC oxidizer), hyperoxia (fraction of inspired oxygen 0.50), or hydrogen peroxide (H(2)O(2)). After treatment with ODQ, SNP-induced cGMP generation was markedly reduced but the effects of cinaciguat were increased by 14- and 64-fold in PPHN fetal PASMC, respectively (P < 0.01 vs. controls). Hyperoxia or H(2)O(2) enhanced cGMP production by cinaciguat but not SNP in PASMC. To determine the hemodynamic effects of cinaciguat in vivo, we compared serial responses to cinaciguat and ACh in fetal lambs after ductus arteriosus ligation. In contrast with the impaired vasodilator response to ACh, cinaciguat-induced pulmonary vasodilation was significantly increased. After birth, cinaciguat caused a significantly greater fall in PVR than either 100% oxygen, iNO, or ACh. We conclude that cinaciguat causes more potent pulmonary vasodilation than iNO in experimental PPHN. We speculate that increased NO-insensitive sGC may contribute to the pathogenesis of PPHN, and cinaciguat may provide a novel treatment of severe pulmonary hypertension.

[1]  P. Tourneux,et al.  Cinaciguat, a soluble guanylate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[2]  S. Wedgwood,et al.  Superoxide dismutase restores eNOS expression and function in resistance pulmonary arteries from neonatal lambs with persistent pulmonary hypertension. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[3]  J. Aschner,et al.  Reactive oxygen species from NADPH oxidase contribute to altered pulmonary vascular responses in piglets with chronic hypoxia-induced pulmonary hypertension. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[4]  W. Seeger,et al.  Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension , 2008, European Respiratory Journal.

[5]  P. Schumacker,et al.  Hyperoxia Increases Phosphodiesterase 5 Expression and Activity in Ovine Fetal Pulmonary Artery Smooth Muscle Cells , 2008, Circulation research.

[6]  D. Hess,et al.  Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation. , 2007, American journal of respiratory and critical care medicine.

[7]  K. Pritchard,et al.  Oxidant stress from uncoupled nitric oxide synthase impairs vasodilation in fetal lambs with persistent pulmonary hypertension. , 2007, American journal of physiology. Heart and circulatory physiology.

[8]  O. V. Evgenov,et al.  NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential , 2006, Nature Reviews Drug Discovery.

[9]  J. Stasch,et al.  Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. , 2006, The Journal of clinical investigation.

[10]  S. Abman,et al.  Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep. , 2005, American journal of physiology. Lung cellular and molecular physiology.

[11]  S. Wedgwood,et al.  Increased hydrogen peroxide downregulates soluble guanylate cyclase in the lungs of lambs with persistent pulmonary hypertension of the newborn. , 2005, American journal of physiology. Lung cellular and molecular physiology.

[12]  Elizabeth M. Boon,et al.  Crystal structure of an oxygen-binding heme domain related to soluble guanylate cyclases. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Stasch,et al.  Identification of Residues Crucially Involved in the Binding of the Heme Moiety of Soluble Guanylate Cyclase* , 2004, Journal of Biological Chemistry.

[14]  S. Wedgwood,et al.  Role of reactive oxygen species in vascular remodeling associated with pulmonary hypertension. , 2003, Antioxidants & redox signaling.

[15]  S. Wedgwood,et al.  Increased Superoxide Generation Is Associated With Pulmonary Hypertension in Fetal Lambs: A Role for NADPH Oxidase , 2003, Circulation research.

[16]  J. Russell,et al.  Paracrine role of soluble guanylate cyclase and type III nitric oxide synthase in ovine fetal pulmonary circulation: a double labeling immunohistochemical study , 2003, Histochemistry and Cell Biology.

[17]  J. Stasch,et al.  NO‐ and haem‐independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle , 2002, British journal of pharmacology.

[18]  A. Hobbs.  Soluble guanylate cyclase: an old therapeutic target re‐visited , 2002, British journal of pharmacology.

[19]  R. Gerzer,et al.  NO-independent regulatory site on soluble guanylate cyclase , 2001, Nature.

[20]  J. Russell,et al.  Pulmonary hypertension alters soluble guanylate cyclase activity and expression in pulmonary arteries isolated from fetal lambs , 2001, Pediatric pulmonology.

[21]  M. Keszler,et al.  Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. , 2000, The New England journal of medicine.

[22]  L. Storme,et al.  Acute Intrauterine Pulmonary Hypertension Impairs Endothelium-Dependent Vasodilation in the Ovine Fetus , 1999, Pediatric Research.

[23]  Chin‐Chung Wu,et al.  Comparison of two soluble guanylyl cyclase inhibitors, methylene blue and ODQ, on sodium nitroprusside‐induced relaxation in guinea‐pig trachea , 1998, British journal of pharmacology.

[24]  J. W. Miller,et al.  Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message. , 1998, American journal of respiratory and critical care medicine.

[25]  R. Busse,et al.  Characterization of NS 2028 as a specific inhibitor of soluble guanylyl cyclase , 1998, British journal of pharmacology.

[26]  A. Halbower,et al.  Chronic intrauterine pulmonary hypertension impairs endothelial nitric oxide synthase in the ovine fetus. , 1997, The American journal of physiology.

[27]  Jesse D. Roberts,et al.  Inhaled Nitric Oxide and Persistent Pulmonary Hypertension of the Newborn , 1997 .

[28]  Cook,et al.  Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. , 1997, The New England journal of medicine.

[29]  B. Mayer,et al.  Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. , 1996, Molecular pharmacology.

[30]  J. Russell,et al.  The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide. , 1995, American journal of respiratory and critical care medicine.

[31]  S. Abman,et al.  Recent developments in the pathophysiology and treatment of persistent pulmonary hypertension of the newborn. , 1995, The Journal of pediatrics.

[32]  M. Kannan,et al.  Modulation of nitric oxide-dependent relaxation of pig tracheal smooth muscle by inhibitors of guanylyl cyclase and calcium activated potassium channels. , 1995, Life sciences.

[33]  D. Ivy,et al.  Ontogeny of NO activity and response to inhaled NO in the developing ovine pulmonary circulation. , 1994, The American journal of physiology.

[34]  G. Schultz,et al.  Mutation of His-105 in the beta 1 subunit yields a nitric oxide-insensitive form of soluble guanylyl cyclase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Jesse D. Roberts,et al.  Inhaled nitric oxide in persistent pulmonary hypertension of the newborn , 1992, The Lancet.

[36]  E. Shaffer,et al.  Low-dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn , 1992, The Lancet.

[37]  D. Cornfield,et al.  Effects of birth-related stimuli on L-arginine-dependent pulmonary vasodilation in ovine fetus. , 1992, The American journal of physiology.

[38]  D. Rodman,et al.  Maturational changes in endothelium-derived relaxing factor activity of ovine pulmonary arteries in vitro. , 1991, The American journal of physiology.

[39]  S. Abman,et al.  Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth. , 1990, The American journal of physiology.

[40]  F. Accurso,et al.  Failure of postnatal adaptation of the pulmonary circulation after chronic intrauterine pulmonary hypertension in fetal lambs. , 1989, The Journal of clinical investigation.

[41]  T. Lincoln,et al.  Regulation of intracellular Ca2+ levels in cultured vascular smooth muscle cells. Reduction of Ca2+ by atriopeptin and 8-bromo-cyclic GMP is mediated by cyclic GMP-dependent protein kinase. , 1989, The Journal of biological chemistry.

[42]  F. Murad,et al.  Cyclic guanosine monophosphate as a mediator of vasodilation. , 1986, The Journal of clinical investigation.

[43]  J. Murphy,et al.  The structural basis of persistent pulmonary hypertension of the newborn infant. , 1981, The Journal of pediatrics.

[44]  M. Heymann,et al.  Persistent pulmonary hypertension of the newborn infant. , 1976, The Journal of pediatrics.

[45]  K. Meurs.  Superoxide Dismutase Improves Oxygenation and Reduces Oxidation in Neonatal Pulmonary Hypertension , 2008 .

[46]  R. Folz,et al.  Hypoxic pulmonary hypertension: role of superoxide and NADPH oxidase (gp91phox). , 2006, American journal of physiology. Lung cellular and molecular physiology.

[47]  J. Russell,et al.  Pulmonary Arterial Contractility in Neonatal Lambs Increases with 100% Oxygen Resuscitation , 2006, Pediatric Research.

[48]  R. Lark,et al.  LOW-DOSE NITRIC OXIDE THERAPY FOR PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN , 2000 .

[49]  A. Friebe,et al.  Soluble guanylyl cyclase: structure and regulation. , 1999, Reviews of physiology, biochemistry and pharmacology.

[50]  J. W. Miller,et al.  Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. , 1998, The American journal of physiology.

[51]  R. Polin,et al.  Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. , 1997, The New England journal of medicine.